The study and its comparison
Eighty-two psychiatrically healthy smokers were randomized to a supervised psilocybin session or a nicotine-patch course. Both groups received thirteen weeks of cognitive behavioral therapy. [1]
At six months, verified prolonged abstinence was 40.5 percent versus 10.0 percent. Sixty-eight participants completed follow-up; the analysis retained randomized denominators. No serious adverse events were attributed to either treatment. [1]
What the finding establishes
The trial was small and unblinded, so expectations and selected eligibility matter. Investigators disclosed grants and relationships with psychedelic and pharmaceutical organizations; full study funding was not established from the abstract. The result is not proof that unsupervised mushroom use safely treats nicotine dependence. [1]
A hypothetical distinction
Imagine two groups receive the same behavioral program but know their assigned treatment. That knowledge can still affect the comparison.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.